No abstract available.
Andropause* ; Humans ; Male*

No abstract available.
Andropause* ; Diagnosis* ; Male

No abstract available.
Andropause* ; Climacteric* ; Humans ; Male ; Male*

PURPOSE: Late-onset hypogonadism (LOH) in aging males is a clinical and biochemical syndrome characterized by a decline in serum testosterone levels. LOH results in various physical and mental disabilities. We evaluated the relationship between serum testosterone levels and symptoms of LOH. MATERIALS AND METHODS: During an andropause screening program, we examined responses to the Saint Louis university androgen deficiency in aging males (ADAM) questionnaire and results on the International Index of Erectile Function (IIEF-5) in terms of clinical symptoms and evaluated serum total testosterone levels for a biochemical diagnosis of LOH in healthy community-living volunteers aged over 40 years. RESULTS: The mean age of the 534 men was 59.1 years (range, 40 to 79 years), and their mean serum testosterone level was 464.1+/-171.9 ng/dL. The serum testosterone level decreased significantly with age. There was a 92.5% positive response rate to the ADAM questionnaire. The percentage of patients whose serum testosterone level was <350 ng/dL among those with a positive response to the ADAM questionnaire was 25.6% (137 patients). The mean serum testosterone level among patients with a positive or negative ADAM questionnaire was 472.4+/-198.5 ng/dL and 487.3+/-165.7 ng/dL, respectively (p>0.05). There was no significant correlation between IIEF-5 scores and serum testosterone levels. CONCLUSIONS: Among men over 40 years of age, 25.6% met the clinical and biochemical diagnostic criteria for LOH. There was no relationship between serum testosterone levels and symptoms of LOH.
Aged ; Aging ; Andropause ; Humans ; Hypogonadism ; Male ; Mass Screening ; Testosterone

PURPOSE: Late-onset hypogonadism(LOH) in the aging male is a clinical and biochemical syndrome characterized by a decline in levels of serum testosterone, and results in various physical and mental disabilities. We aim to evaluate the relationship between serum testostosterone levels and symtpoms of LOH. MATERIALS AND METHODS: As part of an andropause screening program, we examined ADAM questionnaires, IIEF-5 scores, and total serum testosterone levels among healthy volunteers aged over 40 years. RESULTS: The mean age of the 409 men was 59.8 years(range 40~89), and the mean serum testosterone level was 471.5+/-180.2 ng/dl. The serum testosterone level decreased significantly in correlation with age. There was a 92.5% positive response on the ADAM questionnaire. Among patients whose serum testosterone was less than 350 ng/dl, the ADAM questionnaire was positive in 23.7%(n=97). The mean serum testosterone level for men with a positive or negative ADAM questionnaire was 469.2+/-181.8 or 489.2+/-170.5 ng/dl, respectively; this difference was not statistically significant (p=xxx). There was also no significant correlation between IIEF-5 scores and serum testosterone levels. CONCLUSIONS: Among men over 40 years of age, 23.7% met the clinical and biochemical diagnostic criteria for late-onset hypogonadism, and there was no relationship between serum testosterone levels and symptoms of late-onset hypogonadism.
Aging* ; Andropause ; Healthy Volunteers ; Humans ; Hypogonadism* ; Male* ; Mass Screening ; Surveys and Questionnaires ; Testosterone*

Though the causes of aging are genetically determinated, beginning and progression of aging may be mediated by a change of endocrine factors. The change of endocrine factors in aging males widely differ for every man and is less clear than in women resulting in an underestimation of the problem unless he presents with sexual dysfunction and reduced fecundity. Only recently, it has been accepted that the andropause, manifested by decline levels of serum androgen and other key hormones after the 30th year, results in various physical and mental disabilities similar to those experienced by women. With the various type and route, testosterone for androgen supplement therapy has been used properly to treat andropause with a desirable clinical outcome under the standard recommended guideline as well as obviously close monitoring on the long term trial. Additionally, benefit and risk of miscellaneous hormones including dehydroepiandrosterone, growth hormone, melatonin and others is still investigating on andropause patients under the various clinical setting. Nevertheless, it is strongly suggested that hormone supplement therapy restores the quality of life through the improvement of general body functions in senescence with andropause.
Aging ; Andropause* ; Dehydroepiandrosterone ; Female ; Fertility ; Growth Hormone ; Humans ; Male ; Melatonin ; Quality of Life ; Testosterone

There has been a great deal of recent interests in the topic of low testosterone in elderly men, a condition referred to as andropause, ADAM (androgen decline of aging male), or PADAM (partial androgen deficiency of the aging male), or LOH (late onset hypogonadism). Age-related decreases in androgen levels occur gradually and vary considerably among individuals. A low level of testosterone has been implicated as a cause of changes in sexual, physical and behavioral capacity in aging men. Although several observational and interventional studies have demonstrated that androgens have important beneficial functions in the body composition, muscle mass and strength, fat distribution, erythropoiesis, cognition, mood and bone density, and play a key role in male sexual function, a considerable controversy exists regarding the indications of testosterone supplementation in aging male.The objective of this article is to discuss what is known and not known regarding the benefits and risks of testosterone-replacement therapy and the monitoring of men receiving testosterone treatment.
Aged ; Aging ; Androgens ; Andropause ; Body Composition ; Bone Density ; Cognition ; Erythropoiesis ; Humans ; Hypogonadism* ; Male ; Risk Assessment ; Testosterone

The concept of male climacteric syndrome or andropause was advanced 55 years ago based on the fact that some men aged over 50 would present similar clinical symptoms as menopausal women. Since then, many related concepts have been presented to describe this specific period of time in men's life, and controversies have never ceased on this concept and its implication. To represent this unique phenomenon in a very general manner, such terms as male climacteric syndrome (andropause), late-onset hypogonadism, and partial androgen deficiency in the aging male (PADAM) are extensively used in clinical practice at the present time. But strictly speaking, these terms differ significantly, each representing a specific physiological condition. Out of different objectives, researchers might use some of the concepts to design their experiments or summarize related data. But it is very important for them to clarify real intentions and particular characteristics of selected research objects, so as to choose and use a proper concept.
Adult ; Aged ; Androgens ; deficiency ; Andropause ; Humans ; Hypogonadism ; Male ; Middle Aged ; Syndrome

PURPOSE: We evaluated the efficacy and safety of transdermal 1% testosterone gel in Korean men with late-onset hypogonadism from Aug. 2004 to Dec. 2005 in a prospective, fixed-dose, placebo-uncontrolled, open label, multicenter study. MATERIALS AND METHODS: From the 5 urological centers in Korea, a total of 87 male patients older than 40 years who were diagnosed with late-onset hypogonadism with serum testosterone lower than 350 ng/dl or serum free testosterone lower than 73.5 pg/ml were enrolled. Among the 87 enrolled 68 patients completed the daily application of 1% testosterone gel according to the standard consumer guidelines for the full 12-week period. We compared the data at baseline and at 4, 8, and 12 weeks follow-up using the Aging Males' Symptoms (AMS) scale, the International Index of Erectile Function (IIEF)-15, the International Prostate Symptoms Score (IPSS), and the serum levels of total and free testosterone and prostate specific antigen (PSA). RESULTS: The mean age of the patients was 56.5+/-12.7 years. The total scores for the AMS scores at baseline, 4, 8, and 12 weeks were 43.5+/-12.2, 36.6+/-12.3, 33.8+/-11.2, and 34.2+/-11.0, respectively (p<0.0001 vs. baseline). Total and free testosterone levels at baseline were 259.8+/-119.4 ng/dl and 50.5+/-24.7 pg/ml, and at 12 weeks were 594.5+/-376.6 ng/dl and 139.5+/-110.7 pg/ml, respectively (p<0.0001 vs. baseline). IIEF scores increased from 34.7+/-8.5 at baseline to 43.2+/-8.7 at 12 weeks (p<0.0001). There were no significant changes in serum PSA levels. The most commonly reported adverse events were acne and itching at the site of application. The majority of adverse events were mild, reversible, and short in duration. CONCLUSIONS: Testogel(R) showed highly effective clinical and biochemical recovery with good tolerance in Korean men with late-onset hypogonadism.
Acne Vulgaris ; Aging ; Andropause ; Follow-Up Studies ; Humans ; Hypogonadism* ; Korea ; Male ; Prospective Studies* ; Prostate ; Prostate-Specific Antigen ; Pruritus ; Testosterone*

PURPOSE: Severe LUTS (lower urinary tract symptoms) have been considered to be a contraindication to ART (androgen replacement therapy) in PADAM (partial androgen deficiency in aging male) patients. But increasing numbers of patients presenting with PADAM have also LUTS due to the enlarged prostate. We investigated the effect of ART to the prostate in whom LUTS are controlled with alpha-blockers. MATERIALS AND METHODS: Of those patients who visited our clinic for PADAM symptoms and had decreased serum levels of total testosterone( <2.8 ng/ml, Biodata, Italy), men with severe voiding symptoms(IPSS 20~35) were recruited. Oral androgen(testosterone undecanoate 160 mg/day) and doxazosin(2~4 mg/day) were administered. IPSS score, prostate volume by TRUS, and serum PSA were assessed. RESULTS: A total of 25 patients were enrolled. Mean patient age was 63.5(51~89) years and median duration of follow-up was 754 days. Initial prostate volume by TRUS was 34.50+/-10.22 ml. Voiding symptoms evaluated by IPSS score improved significantly from 24.12+/-2.54 to 14.64+/-6.01(p <0.01). Serum PSA level showed no significant change from 1.20+/-0.54 ng/ml to 1.30+/-1.05 ng/ml. CONCLUSIONS: PADAM patients with severe voiding symptoms could be treated with a combination of androgen therapy and alpha-blockers. Further studies with longer follow-up would be required to confirm our results.
Aging ; Androgens ; Andropause ; Follow-Up Studies ; Hormone Replacement Therapy ; Humans ; Male ; Prostate ; Prostatic Hyperplasia ; Testosterone ; Urinary Tract